Skip to content
drillr.ai
Sign up

GENB

Generate Biomedicines, Inc.

NASDAQ · Financial Services · Asset Management · US

$16.39
+0.31%
Ask drillr

  • Aug 25, 2026, 15:22 UTC

    Generate Biomedicines Inc's post-IPO lock-up period is set to expire on Wednesday, allowing insiders, early investors, and major shareholders to sell shares from its $400 million IPO.

    Source:

  • Aug 6, 2026, 11:00 UTC

    Generate Biomedicines Inc. reported its second quarter 2026 financial results, including cash, cash equivalents, and marketable securities of approximately $457.4 million as of June 30, 2026.

    Source: